Published in final edited form as:

IEEE J Solid-State Circuits. 2020 November ; 55(11): 2914–2929. doi:10.1109/jssc.2020.3020789.

Design and Analysis of a Sample-and-Hold CMOS Electrochemical Sensor for Aptamer-based Therapeutic Drug Monitoring

Jun-Chau Chien [Member, IEEE],

Department of Electrical Engineering, Stanford University, Stanford, CA 94305 USA

Sam W. Baker,

Department of Comparative Medicine, Stanford University, Stanford, CA 94305 USA

H. Tom Soh,

Department of Radiology and the Department of Electrical Engineering, Stanford University, Stanford, CA 94305 USA

Amin Arbabian [Senior Member, IEEE]

Department of Electrical Engineering, Stanford University, Stanford, CA 94305 USA

Abstract

In this paper, we present the design and the analysis of an electrochemical circuit for measuring the concentrations of therapeutic drugs using structure-switching aptamers. Aptamers are single-stranded nucleic acids, whose sequence is selected to exhibit high affinity and specificity toward a molecular target, and change its conformation upon binding. This property, when coupled with a redox reporter and electrochemical detection, enables reagent-free biosensing with a sub-minute temporal resolution for *in vivo* therapeutic drug monitoring. Specifically, we design a chronoamperometry-based electrochemical circuit that measures the direct changes in the electron transfer (ET) kinetics of a methylene blue reporter conjugated at the distal-end of the aptamer. To overcome the high-frequency noise amplification issue when interfacing with a large-size ($> 0.25 \text{ mm}^2$) implantable electrode, we present a sample-and-hold (S/H) circuit technique in which the desired electrode potentials are held onto noiseless capacitors during the recording of the redox currents. This allows disconnecting the feedback amplifiers to avoid its noise injection while reducing the total power consumption. A prototype circuit implemented in 65-nm CMOS demonstrates a cell-capacitance-insensitive input-referred noise (IRN) current of $15.2 \text{ pA}_{\text{rms}}$ at a 2.5-kHz filtering bandwidth. We tested our system in human whole blood samples and measured the changes in the ET kinetics from the redox-labeled aptamers at different kanamycin concentrations. By employing principal component analysis (PCA) to compensate for the sampling errors, we report a molecular noise floor (at $\text{SNR} = 1$) of $3.1 \text{ }\mu\text{M}$ with sub 1-sec acquisition time at 0.22-mW power consumption.

Index Terms—

Aptamer; DNA; personalized drug dosing; precision medicine; pharmacokinetics; electrochemical detection; square-wave voltammetry; chronoamperometry; methylene blue; electron transfer kinetics; *in vivo* monitoring; CMOS; implantable; wearable; sample-and-hold circuit; principal component analysis; aminoglycoside; kanamycin

I. INTRODUCTION

Current clinical standard for drug dosing relies on physical parameters, such as age, gender, body weight, and body surface area. Unfortunately, these approaches do not account for individual differences in pharmacokinetics (PK), which describes the absorption, distribution, metabolic, and excretion rate of drugs in the body [1–3]. As the variation in PK can be as large as ten-fold among individuals [4], there is great interest in developing the technology for monitoring and controlling drug concentrations *in vivo* for optimal therapeutic outcomes with minimal toxicity (Fig. 1(a)) [5–7]. Such control is particularly important for drugs with narrow “therapeutic windows” wherein underdosing results in low efficacy and over-dosing can cause acute injury to organs [8–10]. Today, therapeutic drug monitoring (TDM) requires multiple venous blood draws and samples are analyzed using immunoassays [11–12] or high-performance liquid chromatography/mass-spectroscopy (HPLC/MS) [13–14]. These assays require *hours* of processing which is impractical for clinical use. Thus, there is a pressing need for continuous biosensor that can measure drug levels in real-time. Importantly, such a sensor would enable the development of closed-loop systems for automatically delivering optimal doses of drugs to individual patients regardless of their PK profile. (Fig. 1(b)).

To this end, our group and others have previously utilized *aptamers* to achieve continuous detection of drugs *in vivo* [15–21]. Aptamers are “synthetic antibodies” composed of nucleic acids that can specifically bind to the target analytes in complex samples such as the whole blood [22–24]. Importantly, they can be engineered into “aptamer-switches” that undergo *structure-switching* upon target binding in a reversible manner. By conjugating electroactive reporters to the aptamers, the changes in their structure (thus the analyte concentration) can be detected electrochemically. As sample preparation is not needed, aptamer switches are capable of continuous monitoring of biomolecules *in vivo*.

Nevertheless, the current generation of aptamer-based real-time biosensors requires either a continuous drawing of the subject’s blood [15] or wired connection to an implanted device [16], and both systems are only suitable for non-ambulatory patients. To overcome these limitations, we have previously reported a miniaturized CMOS system for implantation [25]. However, this system consumed milliwatts of power, dominated by the signal-to-noise ratio (SNR) requirement in the sensing circuits when interfacing with large-area-electrodes for *in vivo* monitoring. Moreover, the readout utilizes square-wave voltammetry (SWV) with a long acquisition time (~8 sec), leading to an excessively high energy consumption (> 50 mJ/sample). This motivates us to develop circuit techniques that can overcome such a noise-power trade-off

Several electrochemical-sensing current-readout circuits have been developed for *in vitro* DNA and biomolecule analysis [26–31], *in vivo* glucose and lactate monitoring [32–34], and sub-second neurotransmitter detection [35–38]. In these implementation, transimpedance amplifier (TIA) and current conveyor (CC) are two popular circuits topologies for reading small currents. As both employ transconductance amplifiers (OTAs) in feedback to establish proper electrode potentials, it is inevitable to couple the OTA noise to the impedance of the electrochemical cell, resulting in noise amplification when measured at high bandwidth (> 1 kHz). This is especially problematic in our specific applications.

In this work, we present a sample-and-hold (S/H) technique in chronoamperometry (CA) to overcome the noise/power trade-off when detecting aptamer conformation switching [39]. By holding the desired potentials onto the electrodes using capacitors, we successfully record, for the *first* time, the changes in the *electron-transfer (ET) kinetics* of the redox reporters without OTAs. Such an open-loop scheme enables simultaneous reduction in both the circuit noise and the power consumption. As a proof-of-concept, we implemented our S/H electrochemical readout circuit in 65-nm CMOS technology with integrated low-leakage switches (as opposed to PCB-level demonstration). Interfacing with an aminoglycoside aptamer [15], we measured samples contained different kanamycin concentrations and achieved a limit-of-detection (LoD) that is on-par with benchtop laboratory instruments. Built upon [39], this paper provides more details regarding the signal transduction mechanism and the analysis that assists the mapping between the electronics noise and the measurement uncertainty in molecular concentration. The issue of sampling error will be discussed, and a compensation technique is presented.

This paper is organized as follows. Section II describes the sensing mechanism and the detection schemes for the aptamer switches. The proposed circuit architecture, signal and noise analysis, as well as its implementation are introduced in Section III. Section IV presents the experimental results, covering both the electronics characterization and assay experiments. Conclusions are presented in Section V.

II. APTAMER SWITCHES

A. Sensing Mechanism

As described above, our group has utilized structure-switching aptamers to achieve real-time detection of small-molecule drugs *in vivo* [15][17]. Using the aminoglycoside aptamer as an example (Fig. 2), the binding to the target molecules promotes a more thermodynamically stable *stem-loop* structure (folded) instead of a linear and flexible structure (unfolded). By conjugating the aptamers with a methylene blue (MB, $C_{16}H_{18}ClN_3S$) reporter at the distal end of the DNA, such a conformation change can be detected by measuring the differences in the electron-transfer kinetics of MB through its sensitivity to the diffusion distance versus the underlying electrode [40–41]. The highest ET kinetics occurs when the MB is closer to the electrode, resulting in a larger electrical current when measured in voltammetry. In this way, higher drug concentration will cause more aptamers being switched into the stem-loop configuration, and thus a larger accumulated signal.

In our system, these aptamers are immobilized at the tip of a sensing probe, which can be implanted directly into a vein for measuring drug concentration in blood plasma.

B. Square-wave Voltammetry

The states of the aptamers are generally measured using square-wave voltammetry (SWV; Fig. 3(a)) [15–16, 40–41]. Unlike cyclic voltammetry (CV), SWV measures the ET kinetics through continuous modulation of the MB states using a small-amplitude square-wave superimposed on a stepping voltage established between a reference (RE) and a working electrodes (WE). This effectively separates the non-Faradaic currents (charging and discharging currents of the interfacial double-layer capacitance) from the desirable Faradaic components (from redox reactions), relaxing the dynamic range requirement and enhancing the sensitivity [40]. Fig. 3(b) depicts example measurements at different kanamycin concentrations (in buffer) using a commercial potentiostat (Palmsens EmStat3 Blue). To mitigate sensor drifts, we employ kinetic differential measurement (KDM) technique [15], which takes advantage of the sensitivity difference measured at two SWV frequencies (e.g. 400 and 60 Hz) to reject common-mode drift while preserving the desired signal (Fig. 3(c)). The molecular noise floor, defined at SNR = 1, is 1.5 μ M for aminoglycoside aptamer with a dissociation constant (K_D) of 0.5 mM for kanamycin (extracted from the binding curve in Fig. 3(d) with a Langmuir isotherm model). These numbers will be used later for benchmarking electronics performance. One critical drawback of SWV is the long scanning time (~ 8 sec per acquisition), which translates to significantly higher energy consumption per readout sample.

C. Chronoamperometry

Though SWV has been the mainstream for electrochemical-based aptamer sensing, chronoamperometry (CA) has recently been re-investigated for redox-coupled DNA detection [42–43]. As shown in Fig. 4, chronoamperometry operates by pulsing the electrode potential ($V_{WE} - V_{RE}$) between two largely-separated voltage levels ($|V_1 - V_2| > 200$ mV) to modulate the energy states of the redox molecules from the fully-reduced toward oxidation (and vice versa). The kinetics of the electron transfer is then probed *directly* through measurements of the decaying current transients. Chronoamperometry offers three main advantages over SWV: (1) higher temporal resolution due to the absence of potential scanning; (2) reduced sensitivity to the drifts in the absolute current (rate measurements); and (3) minimal influence from background interference due to a limited voltage-scanning range (Table I). More importantly, its operational simplicity offers an opportunity to incorporate circuit technique for simultaneous power and noise reduction, as will be discussed in Section III-C. Nevertheless, CA is more sensitive to the instability of the RE potential because any drift in the redox potential will remain undetectable and leads to signal variation. Such an issue can be solved with a hybrid scheme using SWV (or cyclic voltammetry) to frequently calibrate and re-adjust V_1 and V_2 (Appendix A provides more detail on this approach). A similar technique is also presented in [37] for dopamine detection. In this work, the information on aptamer-folding kinetics is extracted from the current transients as the reduction potential is stepped from -0.2 V to -0.4 V (Fig. 4(b)). The same information can also be extracted through the oxidation process (Fig. 4(c)) with the oxidation potential stepping from -0.5 to -0.3 V. The period of the square wave is

determined by the minimum time needed to fully reduce or oxidize the MB molecules prior to the voltage stepping and is empirically found to be > 100 msec.

D. Measurement Uncertainty

It is crucial to study factors that impact the performance of the biosensor performance *in vivo*. Generally, the uncertainty in the assay (e_{assay}^2) is summarized as [44]:

$$e_{assay}^2 = e_{n,electronics}^2 + e_{n,MSN}^2 + e_{background}^2, \quad (1)$$

where $e_{n,electronics}^2$ refers to the noise from the measurement electronics, $e_{n,MSN}^2$ represents the shot noise induced by both the molecular binding and the electron transfer in the redox reaction, and $e_{background}^2$ includes all other uncertainty such as drifts, sensitivity degradation, non-specific binding, and curve-fitting errors. We carried out both *in vitro* (using flowing human whole blood) and *in vivo* (using an anesthetized rodent) studies to monitor aptamer responses under changing drug concentration. Fig. 5 demonstrates an example of *in vivo* setup, our implantable device (which will be used later when testing the proposed sensor circuits), and the measurement results (in SWV). We found that $e_{background}^2$ occurs at a longer time scale (~ hours) and can be corrected with *in vitro* calibration, similar to the approach used in continuous glucose monitoring (CGM) system [45], and $e_{n,MSN}^2$ is negligible due to relatively high target concentration in our drug-dosing application. On the other hand, $e_{n,electronics}^2$ plays the dominant role in determining the sample-to-sample variance. This is indeed the case in our earlier CMOS implementation [25] where we measured a molecular noise floor of only 18 μM ($\approx 0.036K_D$).

Note that V_{peak} in the acquired SWV curves is shifted by ~15 mV in the 3hr *in vivo* experiments due to the drift in the pseudo-RE. We adjusted the upper and lower bounds of the scanned voltages to re-center V_{peak} for measurement consistency. As mentioned earlier, such an adjustment is particularly important in CA measurements.

E. Implantable Probe

To fit into the vein of a rodent, we prepare an implantable probe (Fig. 5(b)) consisting of a bundle of a gold (Au, the WE) and a silver chloride (Ag/AgCl, the RE) wires, all at 75- μm diameter. The sensing area on the gold electrode is defined using heat-shrinkable polymer tubing. Here we employed a two-electrode electrochemical cell instead of a standard three-electrode setup. This is possible because the electrolyte resistance between the RE and WE is sufficiently small such that the IR drop between them is negligible. A detailed characterization is provided in Appendix B. The aptamers are immobilized onto the oxidized gold wire through thiol bonds (S-H). The device is implanted through the femoral vein using a 20-gauge catheter. The system can be scaled up by bundling extra gold wires functionalized with different aptamers to monitor more than one type of drugs. Fig. 5(c) demonstrates the results of a multiplexed drug detection with bolus administration of two drugs (kanamycin and ampicillin) intravenously at different time instants. The sequence of aptamers for detection ampicillin is adapted from [46]. We note that the ampicillin aptamer

(Channel 2) exhibits some cross-reactivity with kanamycin as shown in Fig. 5(c). This cross-reactivity poses a critical problem for many small-molecule aptamers [54]. This problem can be addressed by using a panel of aptamers for the target analyte, similar to the strategies used in electronic-nose systems [55–57]. Appendix C provides more discussions on the lifetime of the aptamer sensors and the potential causes of signal degradation along with techniques to improve the aptamer longevity.

It is critical to point out the importance of aptamer packing density on the electrode. On one hand, excessively high packing density induces undesired inter-molecular interactions among the aptamers and cause sensitivity degradation. On the other hand, excessively low packing density produces small signals. In general, we prepare the aptamers at a surface density of 1% which produces an optimal signal [47]. This translates to a 10-nm average spacing among each aptamer assuming each one occupies a real estate of 1 nm^2 , or $10^{12}/\text{cm}^2$. To cope with such a low surface density, we have chosen a relatively large area ($> 0.25 \text{ mm}^2$) in our implantable sensing probe to achieve a sufficiently large signal without the need of surface roughening [48] and to avoid the issue of irreversible oxygen reduction encountered when using a small-area electrode [49]. Inevitably, such a large cell capacitance will have system design implications and causes significant noise amplification, which will be discussed in Section III-A.

III. APTAMER-SENSING CIRCUITS

A. Signal Analysis and Design Specification

In this section, we focus on understanding the impact of electronics noise to the LoD of the measured drug concentration in chronoamperometry. Before starting, it is important to mention that the extraction of the concentration information from the decaying current waveforms involves curve-fitting technique. Such an “averaging” effect on the electronics noise must not be neglected otherwise the design specification will be overly conservative. Our approach is detailed in the next paragraph.

To simplify the noise analysis, we model the ET kinetics using an exponential function with a time constant τ_0 ¹ (Fig. 6):

$$i_{redox}(t) = \frac{\alpha Q_T}{\tau_0} e^{-\frac{t}{\tau_0}}. \quad (2)$$

In (2), Q_T represents the total charge when all the MB electrons (two electrons per molecule) are fully transferred during the redox reaction, and α accounts for the percentage of the MB that participates in the electron transferring. The weighting term ensures that the total amount of transferred charges under varying τ_0 remains constant. Next, we perform Monte Carlo simulation with Gaussian white noise added to the time series and the curve is fitted (*fit* function in Matlab) to extract the kinetical time constant. The procedure is repeated multiple times at different noise magnitude, and the uncertainty (one standard deviation) in

¹Deriving the actual current response under overpotential activation requires solving the mass transport kinetics using Fick’s law of diffusion and Butler-Volmer equation [50–51], and this often requires numerical simulation based on the electrode geometry [41].

the time constant is calculated. Finally, we map the electronics noise to the molecular concentration assuming a known sensitivity ($S = \tau_0 / [C]$).

Fig. 6 shows the calculated current for a 0.25-mm^2 ($= 500\text{ }\mu\text{m} \times 500\text{ }\mu\text{m}$) electrode at 1% packing density. Here we assume a time-constant ratio of 2:1 at high and low target concentration based on our earlier experiments. According to our simulation, an additive noise magnitude of $< 0.25\text{nA}_{\text{rms}}$ (sampled at 2.5 kHz over 10 msec) is needed to ensure that the concentration uncertainty is kept below $0.01 K_D$. The readout IC requires approximately 10 bits of dynamic range with the maximum signal determined by the fastest electron transfer kinetics ($k \sim 440\text{ 1/sec}$) [40]. We summarize the design specification for both the biosensor and the electrochemical-sensing interface circuits in Table II.

The electron transfer kinetics is also impacted by the use of the self-assembly monolayer (SAM) for passivating the sensor surface. Such passivation is necessary to block the undesirable redox reaction from the electroactive biomolecules presented in the biofluids, including oxygen, uric acids, ascorbic acids, and etc. In our *in vivo* assay, we employ 6-mercapto-1-hexanol (MCH; $\text{C}_6\text{H}_{14}\text{OS}$, a hydroxyl-terminated six-carbon chain) to serve this purpose and to balance between electron transfer kinetics and the stability of the SAM [52]. The presence of the passivation also affects the double-layer capacitance at the electrode-electrolyte interface. The measured double layer capacitance (C_{DL}) exhibits a unit capacitance of 36 and 215 nF/mm^2 in saline sodium citrate ($1\times\text{SSC}$) buffer with and without the passivation, respectively. We found that C_{DL} is lower in EDTA-treated human whole blood, presumably due to the lower ionic strength. The estimated C_{DL} for our implanted electrode is also included in Table II. In our circuit design, we have started with $C_{\text{DL}} = 100\text{ nF}$ as the worst-case scenario (assuming no passivation and taking into account variation in the sensor surface area).

B. Electrochemical-sensing Interface Circuits

Fig. 7 shows the conventional electrochemical readout circuit [25]. It consists of a bandgap reference (BGR) voltage generator, a reference buffer (A_1), an R-2R digital-to-analog converter (DAC), a control amplifier (A_2), a current conveyor (CC) with feedback amplifier (A_3), and an analog-to-digital converter (ADC). The total noise current, when referred to the input of the current conveyor (or WE), is the power sum of the electrochemical-cell-dependent noise and the additive noise from the current conveyor:

$$\overline{i_{n,WE}^2} = \overline{i_{n,1}^2} + \overline{i_{n,2}^2}, \quad (3)$$

$$\overline{i_{n,1}^2} = \frac{\overline{v_{n,BGR}^2} + \overline{v_{n,DAC}^2} + \overline{v_{n,A1}^2} + \overline{v_{n,A2}^2} + \overline{v_{n,A3}^2}}{|Z_{\text{cell}}|^2}, \quad (4)$$

$$\overline{i_{n,2}^2} = \overline{i_{n,bias}^2} + \overline{i_{n,M1}^2} + \overline{i_{n,M2}^2} + \frac{1}{N_{\text{mirror}}^2} \overline{i_{n,ADC}^2}. \quad (5)$$

In (4), $Z_{\text{cell}} (= R_s + 1/j\omega C_{\text{DL}})$ models the electrical impedance of the electrochemical cell, and $\overline{v_{n,BGR}^2}$, $\overline{v_{n,DAC}^2}$, $\overline{v_{n,A1}^2}$, $\overline{v_{n,A2}^2}$, $\overline{v_{n,A3}^2}$ are the output noise of the bandgap reference, the DAC, and the input-referred voltage noise of the amplifiers A_{1-3} , respectively; in (5), N_{mirror} is the gain of current mirror, $\overline{i_{n,M1}^2}$, $\overline{i_{n,M2}^2}$, $\overline{i_{n,Ibias}^2}$, and $\overline{i_{n,ADC}^2}$ represent the noise current from M_1 , M_2 , I_{bias} , and the ADC, respectively. According to (4), a simultaneous increase in the power consumption from each noise-contributing block is necessary to effectively reduce the overall noise. In addition, the reduced impedance from the large cell capacitance (C_{DL}) at frequencies above 1 kHz causes significant noise peaking and dominates the overall noise performance. In other words, there exists a noise-power trade-off when interfacing with our implantable electrodes. Fig. 7(b) shows an illustration of the power spectral density (PSD) where ω_{peak} is the peaking frequency and occurs when $\overline{i_{n,1}^2} = \overline{i_{n,2}^2}$. Assuming that the BGR noise is effectively filtered, $R_s \ll 1/\omega_{\text{peak}} C_{\text{DL}}$, and each component contributes equally, (4) and (5) are lumped to:

$$\frac{\overline{i_{n,1}^2}}{\Delta f} = N_1 (\omega_{\text{peak}} C_{\text{DL}})^2 \frac{8kT\gamma}{gm_1}, \quad (6)$$

$$\frac{\overline{i_{n,1}^2}}{\Delta f} = N_2 (4kT\gamma gm_2). \quad (7)$$

In (6) and (7), gm_1 is the transconductance of the input transistors in the amplifiers A_{1-3} , gm_2 is the transconductance of the transistors M_1 , M_2 , and I_{bias} in the current conveyor, k is the Boltzmann constant, T is the absolute temperature, γ is the technology-dependent noise factor, and N_1 and N_2 are the numbers of noise components. In (6), the output noise voltage of the R-2R DAC (with a unit resistor of R_0) is converted to the input-referred noise of a transistor having an equivalent gm of γ/R_0 . Assuming $N_1 = N_2$, we have:

$$gm_1 \approx \frac{2}{gm_2} (\omega_{\text{peak}} C_{\text{DL}})^2. \quad (8)$$

With a C_{DL} and gm_2 of 100 nF and 30 μS (at $I_{\text{bias}} = 2\mu\text{A}$), a gm_1 of 26.4 mS is needed for ω_{peak} at 1 kHz. Such a gm requirement leads to excessive-high current (~ 2 mA per input transistor) for an optimistic 150 pA_{rms} when integrated over 2.5 kHz of bandwidth (without considering the flicker noise and assuming brick-wall filtering). Note that the need for high bandwidth is the main difference in power consumption requirement when compared to glucose sensors employing fixed-potential amperometry with excessive filtering (below few Hz) [32–33]. In enzymatic glucose sensors, the glucose oxidase (GOx) enzyme continuously oxidizes the glucose to generate an electrical current in proportional to the target concentration (directly or through reaction byproducts such as hydrogen peroxide). On the other hand, the total number of the methylene blue tethered to the aptamer sensors remains constant regardless of the target concentration, and cyclic redox reaction through the modulation of the electrode potentials is necessary to read out its response within a few milli-seconds. In other words, it is the detection electrochemistry that leads to such a drastic difference in the design specification.

C. Sample-and-Hold Sensor Architecture

Fig. 8 demonstrates the conceptual operation of the proposed sample-and-hold (S/H) electrochemical interfacing circuit. The central idea is to sample and hold the settled potentials onto capacitors C_1 and C_2 presented at both the reference (RE) and working electrodes (WE) using two switches (S_1 and S_2) such that the noise-contributing amplifiers can be disconnected and powered down during redox-current recording. Fig. 8(b) and 8(c) show the two modes of the operation. During the recording phase, the input-referred noise (IRN) current is only dominated by the common-gate device (M_1) and its mirroring load (M_2) and is insensitive to C_{DL} , leading to superior low noise at low-power operation. In this way, we have essentially eliminated the noise from Eq. (4). Taking into account the impedance of the electrochemical cell (Z_{cell}) and the input impedance from M_1 (Z_{in}) while assuming that the ADC noise is effectively attenuated by the mirror gain, the IRN noise during the recording state can be re-written from (4) as

$$\overline{I_{in, IRN}^2} \approx \overline{I_{n, I_{bias}}^2} \cdot \left| \frac{z_{cell}}{z_{in} + z_{cell}} \right|^2 + \overline{I_{n, M1}^2} \cdot \left| \frac{z_{in}}{z_{in} + z_{cell}} \right|^2 + \overline{I_{n, M2}^2}, \quad (9)$$

$$\approx \overline{I_{n, M1}^2} + \overline{I_{n, M2}^2}. \quad (10)$$

In (10), the approximation assumes that both M_1 and the current source are sized with the same overdrive voltage. In reality, M_1 is designed to have a much larger size to supply high current during the settling phase (thus a much lower overdrive voltage), making M_1 the dominant source of noise (> 60% from the simulation results).

The degree of power reduction from this duty-cycling method is determined by the duration ratio between the tracking and the holding phases. Inevitably, there will be sampling noise including those from the amplifiers, charge injection, clock feedthrough, and environmental electromagnetic interference (EMI). This will cause undesirable modulation of the electrode potentials which affect the kinetics of the electron transfer, and thus the measurement uncertainty. As will be demonstrated later in Section IV-B, this can be compensated using principal component analysis (PCA) based on the multiple parameters extracted from the measurements.

In the design, C_1 (1 μ F, an off-chip ceramic capacitor) is chosen to supply a sufficient amount of charge for the redox reaction without much perturbation to the electrode potential (~ 1 mV under complete redox reaction) while C_2 (40 pF, on-chip MOSCap) is selected to minimize the sampling noise, charge injection, and clock feedthrough. As the detection is based upon the extraction of the time constant (similar to ratiometric measurement technique), the impact from both the sampled offsets and the flicker noise is minimal. Therefore, mitigation techniques such as chopper stabilization and correlated double sampling are not incorporated. On the other hand, the flicker noise introduced by M_1 , M_2 , and I_{bias} cannot be neglected. Fortunately, the low frequency noise (< 100 Hz) is effectively rejected because the kinetics information is extracted within the first 10 msec after the step change in potential. Therefore, we can simply size the devices to limit the amount of flicker noise. Due to its open-loop nature, the input impedance of the current buffer M_1 is

elevated during the recording phase. In turn, this will cause drifts in the WE potential by the modulation from the time-varying redox currents. Therefore, it is critical to supply a decent amount of bias current ($2\text{ }\mu\text{A}$) to keep such a modulation within an acceptable margin. The simulated input impedance is $\sim 16\text{ k}\Omega$ at the typical corner, and the WE potential deviates no more than $\sim 3.3\text{-mV}$ with $\pm 200\text{nA}$ of current change.

D. Circuits Implementation

Fig. 9 shows the block diagram, the timing diagram, and the schematics of the proposed S/H electrochemical interfacing IC. The operation can be separated into four phases. Prior to each potential stepping, all the amplifiers are enabled and S_1 and S_2 are closed for 1 msec to re-establish the potentials. Upon $\pm 0.2\text{-V}$ potential stepping, two charge pump switches (S_3 and S_4) embedded inside the WE current conveyor are closed for $400\text{ }\mu\text{sec}$ for fast charging and discharging. Afterward, a $100\text{-}\mu\text{sec}$ linear settling period is allocated, followed by the opening of S_1 and S_2 to hold the potentials and to disable the amplifiers. When operated continuously, the amplifiers are duty-cycled at 1.5% ($=1.5\text{ msec}/100\text{ msec}$). We extract the kinetics of the electron transfer rate from the recorded current transients. Most of the signal-of-interest lies within the first 10 msec after the potential stepping, indicating that the ADC can be further powered off during the other 90 msec. We note that the electron-transfer kinetics for short-stranded aptamers has a time constant (τ_0) of $\sim 1.4\text{ msec}$. Based on this, we allocated the settling-time of 0.5-msec . Similarly, we allocated a 100-msec hold-time based on the time needed to fully reduce or oxidize the MB. Lastly, the 1-msec enabling period prior to the stepping is to bring back the electrode potentials to its designated voltages to ensure consistency in each settling.

Identical Miller-compensated two-stage amplifiers (Fig. 10(a)) with a tail bias of $320\text{ }\mu\text{A}$ are used in the implementation of A_{1-3} except that the compensation RC network is removed for the RE driver (A_2). This guarantees the settling speed of the amplifiers under a $1\text{-}\mu\text{F}$ load, and also serves as benchmarking comparison when configured into a conventional electrochemical sensor with feedback enabled. Note that bias currents in the amplifiers A_1 and A_3 in this particular design is selected to achieve $\sim 1\text{nA}_{\text{rms}}$ noise floor when loaded with a 100-nF cell capacitance (mainly for comparison purpose); thus, it is noise-limited rather than settling-limited and is sub-optimal in the proposed S/H scheme. An estimation on the degree of power reduction is provide in Appendix D. The redox current is amplified by the regulated cascode (RGC) current mirror with programmable mirror ratio (Fig. 10(b)) and is digitized by a dual-slope ADC (Fig. 10(c)). The full scale ($0.5 \sim 2\text{ }\mu\text{A}$) and the integrating capacitance (1b control) in the ADC, as well as the RGC mirror ratio (1:8) are made adjustable to expand the total dynamic range by nearly 40 dB . No explicit filtering stage is incorporated; instead, we rely on the integration from the ADC with a window size of $50\text{ }\mu\text{sec}$ and is thus sub-optimal. To minimize leakage current during the hold phase, S_1 and S_2 are implemented with tri-switches and an analog keeper using a feedback unity-gain buffer (rail-to-rail input folded cascode amplifier, Fig. 10(d)). In this prototype study, the sensing IC is clocked at 30 MHz with a signal generator for testing flexibility. The programmability is offered by on-chip scanning registers and finite-state machine (FSM), and is controlled with an off-chip FPGA.

IV. EXPERIMENTAL RESULTS

A. Electrical Characterization

The prototype circuit is implemented in TSMC 65-nm CMOS technology. Fig. 11 shows the circuit micrograph with the core occupying an area of 0.385 mm^2 , mainly dominating by the area of the three OTAs (A_{1-3}). All analog blocks are implemented with thick-oxide transistors and is powered from a 2.5-V supply through on-chip LDO. The digital circuits, including ADC counter and control registers, are operated at 0.9 V. To mitigate EMI, the circuit is powered using battery at 3 V, and the whole system is shielded with a Faraday cage except the FPGA and the clock source. Fig. 12 shows the schematic and the photo of the measurement setup.

We first perform electrical characterization of the interface circuits. Specifically, we evaluate the settling behavior of the WE and RE potentials under abrupt changes. With the electrode impedance model (at a C_{DL} of 100 nF) shown in Fig. 13(a), $V_{WE} - V_{RE}$ achieves complete settling at a maximum stepping amplitude of 425 mV. This is $2\times$ the desired amplitude (200 mV) given an overestimated C_{DL} , and thus it is sufficient to cover the variation in the sensor surface area. Fig. 13(b) also exhibits an example case when incomplete settling is observed. In this case, we attempt to step $V_{WE} - V_{RE}$ by 450 mV. The “slewing” behavior after the S/H operation in the potential step-down phase is due to continuous discharging of C_{DL} by the I_{bias} (at a slew rate of 10 V/sec). This indicates that M_1 is not able to turn on before the hold operation. On the other hand, we observe a proper settling behavior in the potential step-up phase. This is because M_1 serves as a class-AB output stage and thus a higher current can be supplied to facilitate a faster settling.

Next, we compare the sensor noise performance with and without the S/H technique. To do so, a sinusoidal voltage is injected through a 1-M Ω off-chip resistor and the samples are acquired during the hold phases at an extended time (0.5 sec). Fig. 14 compares the measurement results. Without the S/H, high-frequency noise-peaking from the 100-nF C_{DL} is observable and the integrated noise over 2.5 kHz is 4.36 nA_{rms}. On the other hand, a minimum IRN of 15.2 pA_{rms} is measured with S/H enabled and stays insensitive to different C_{DL} loading below 100 nF. The measured 1/f corner-frequency is ~ 300 Hz. In these electrical testing, the mirror gain and the ADC parameters are adjusted accordingly to ensure sufficiently low quantization noise. This also explains the difference in the DC offset presented in the time-domain waveforms. The amplitude of the injected sinewaves is also adjusted to fall within the dynamic range of the ADC. When interfacing with the aptamer sensors, these parameters are re-adjusted according to the measured current level. The maximum current that the current conveyor can measure is 1.6 μA_{pp} with HD2 of 45 dB. The instantaneous dynamic range (DR) is about 60 dB, which is sufficient in our application. The cross-range DR is ~ 100 dB ($= 1.6 \mu\text{A}_{pp} / 15.2 \text{ pA}_{rms}$).

The 10-bit R-2R DAC has a DNL and INL of $+0.9/-0.58$ and $+1.2/-0.65$ LSB, respectively. Based on our assay experiments, the requirement in the absolute accuracy is not as stringent so long as it is consistent across measurements. The circuit consumes 5.25 mW at 2.5 V without the S/H technique. Once S/H is enabled, all the power-hungry OTAs (but not ADC) are duty-cycled, reducing the total power to 0.22 mW.

B. Assay Experiments

We prepare a two-electrode sensing probe functionalized with aminoglycoside aptamers and carry out the assay in target-spiked human whole-blood samples *in vitro*. The immobilization steps are similar to those in [15] and are summarized as follows: (1) define the sensor surface area on the gold electrode using heat-shrink tubing; (2) perform electrochemical cleaning in 0.5- and 0.05-M H_2SO_4 solution using three CV scans at 100 mV/sec from -0.4 to 1.5 V; (3) incubate the sensor surface with $1\text{-}\mu\text{M}$ aptamer solution in saline sodium citrate ($1\times$ SSC) buffer for an hour at room temperature; (4) passivate the sensor surface with 6-mercapto-1-hexanol (MCH) at 6 mM in DI-water for two hours at room temperature; (5) store the device in $1\times$ SSC at 4°C overnight to stabilize the SAM layer. Afterward, the device is ready to use and has a shelf life of one week. The human whole blood samples are purchased from BioIVT Inc. and are spiked with 200-mM kanamycin monosulfate (prepared in $1\times$ SSC buffer) followed by serial dilution to the desired concentrations. The same electrode is tested from low to high target concentration. To avoid sample contamination, we manually swap sample tubes and perform chronoamperometry testing. No washing has been applied between each measurement. We record V_{WE} and V_{RE} as well as the current transients for analysis.

Fig. 15 presents the measured $V_{\text{WE}} - V_{\text{RE}}$ waveforms with the actual aptamer-immobilized sensing device to study its settling and drooping. This is particularly important as the cell impedance critically depends on the integrity and the quality of the self-assembly monolayer (SAM). From Fig. 15(c), voltage changes in the region-of-interest (ROI, the first 10 msec after potential stepping) is $\sim 4.5\text{ mV}$, and its shape is correlated to the exponentially changing current transients. The drooping over a half-cycle duration (50 msec) is $\sim 0.2\text{ V/sec}$, indicating there exists a constant background leakage current of $\sim 2\text{ nA}$ (assuming C_{DL} of 10 nF) and can be viewed as the “offset” current caused by the pinholes in the SAM. A 3-mV_{pp} sampling error in $V_{\text{WE}} - V_{\text{RE}}$ is observed from 20 consecutive recorded pulses, as shown in Fig. 15(a). This is much higher than the simulated sampling noise from the circuits alone and is therefore attributed to the finite pick-up from EMI effects. Such a sampling noise indeed affects the extracted kinetics and we will present a compensation technique in the next paragraph.

Fig. 16 shows the measured kinetics from *normalized* (to the sample at $t = 0$) current transients at 0 , 0.5 , and 2 mM kanamycin concentration. Difference in the electron transfer kinetics at different target concentrations is observed. Next, we fit the *un-normalized* current transients using a two-term exponential function shown below to extract both the kinetics (τ_1 and τ_2) and the absolute current level (I_1 and I_2):

$$i(t) = I_1 e^{-\frac{t}{\tau_1}} + I_2 e^{-\frac{t}{\tau_2}}. \quad (11)$$

Fig. 17(a) plots the extracted τ_1 and I_1 at different concentration levels. Two observations are made from this figure. First, at each concentration, there exists high uncertainty in τ_1 alone. The extracted molecular noise floor solely based on τ_1 (defined at $\text{SNR} = 1$) is $57\text{ }\mu\text{M}$ (11% of K_D). We attribute this to the random modulation in the electrode potentials during the S/H operation, as shown in Fig. 17(b). In other words, in each chronoamperometric

cycle, the perturbation on the held potentials causes slight modulation in the electron transfer kinetics, as described by the Butler-Volmer model [41]:

$$k_{oxidation} = k_0 e^{-\alpha \frac{F}{RT}(E - E_0)}, \quad (12)$$

$$k_{reduction} = k_0 e^{(1 - \alpha) \frac{F}{RT}(E - E_0)}. \quad (13)$$

In the above equations, k_0 (~0.4 cm/sec) is the heterogeneous rate constant, α is the electron transfer coefficient (~0.37), F is Faraday constant, R is the ideal gas constant, T is the absolute temperature, E and E_0 are the applied potential and the standard potential (V), respectively. The effect can also be understood with the analogy of electrical impedance spectroscopy in which the variation in the amplitude of the excitation sinusoids will cause error in the measured output current. A simple remedy is to include extra sensing channels that monitor the electrode potentials and perform compensation afterward at the cost of additional power consumption and silicon area. On the other hand, based on the second observation from Fig. 17(a), there exists a strong correlation between τ_1 and I_1 , and we believe I_1 serves as an indirect indicator for the error induced by the sampled electrode potential. Similar correlation is found between τ_1 and the first sample ($t = 0$) of each current transient. By taking advantage of this, we perform principal component analysis (PCA) to effectively compensate for the measured uncertainty. Fig. 18(a) plots the time series of the principal components after rotating the data. A significant reduction in the noise variance is demonstrated. Fig. 18(b) plots the principal components (mean and standard deviation) at different concentrations. An improvement in molecular noise floor from 57 to 12.3 μM is achieved. As chronoamperometry offers high temporal resolution (5 ~ 10 Hz), we further perform 10-point boxcar averaging to understand its limit and to compare with those measured using SWV. After moving average, a noise floor of 3.1 μM is measured at an acquisition rate of 1 Hz with drifts removed. Table III summarizes the molecular noise floor (SNR = 1) and the limit-of-detection (LoD, defined as SNR = 3.3 according to [58]) acquired from different electronics and voltammetry techniques.

Table IV provides a comparison with the state-of-the-art electrochemical sensing circuits. To the best of authors' knowledge, this is the first comprehensive discussions on the design of the customized readout circuit for aptamer-based electrochemical biosensors. In addition, the S/H technique presented here, which takes advantage of the properties in the voltammetry, achieves a simultaneous reduction in both IRN and power consumption without suffering from the noise penalty of large electrochemical-cell loading. We recognize that a direct comparison among techniques are difficult to make due to differences in the biosensing elements, its associated sensitivity, and other experimental parameters including the type of the biofluids for the intended applications. For example, [28] employs a similar biosensing element to this work (single-stranded DNA with methylene blue reporters) for *in vitro* hybridization-based DNA analysis. As the hybridization process can take tens of minutes and hybridized duplex DNA offers a greater change in the signal (duplex DNAs are more rigid and the MB is spaced further away from the underlying electrode), low-scan-rate cyclic voltammetry (CV) with excessive filtering (50Hz) can be employed to greatly reduce noise.

On the other hand, [33] and [34] both employ enzymatic biosensors and demonstrate fully-integrated “injectable” implants. As mentioned in Section III-B, these enzymatic biosensors generally offer higher sensitivity and its detection chemistry permits constant-potential amperometry, thus reducing the overall required system power. Given these considerations, and the fact that our amplifiers are disconnected during the recording phase, we decided not to present a figure-of-merit (FoM) as a means of comparison. Nonetheless, when compared with other aptamer measurements using standard SWV mode, the proposed S/H technique reduces both the circuit noise and the power consumption by a factor of $286\times$ ($= 4.36$ nArms / 15.2 pArms) and $23\times$ ($= 5.25$ mW / 0.22 mW), respectively. The reduction in energy consumption per acquisition is particularly important for long-term recording. Furthermore, we achieve an improvement in the temporal resolution by $80\times$ ($= 8$ sec per acquisition in SWV mode versus 0.1 sec per acquisition in CA mode), or $8\times$ when an averaging of ten samples is applied to the CA samples. Finally, we report an improvement in the molecular noise by $1.45\times$ ($= 18$ μ M / 12.3 μ M), or $5.8\times$ ($= 18$ μ M / 3.1 μ M) with averaging applied to the CA samples.

V. CONCLUSION

In this work, we present the design and the analysis of an electrochemical circuit whose input-referred current noise is insensitive to the electrode capacitive loading to enable low-power monitoring of therapeutic drugs using redox-labeled structure-switching aptamers. We take advantage of the waveform simplicity in chronoamperometry and incorporate sample-and-hold operation around the electrochemical cell to store the desired electrode potentials using noiseless capacitors during the current-recording phase. In the proposed solution, the noise dominating OTAs are disconnected from the sensor and can be disabled, and simultaneous low-power and low-noise recording is achieved. We recorded an IRN of 15.2 pA_{rms}, and the performance is insensitive to the size of the cell-capacitance. We also addressed the issue of sampling error on the held potential using PCA-based signal processing. Using these strategies, we achieved an LoD of 3.1 μ M in kanamycin concentration using an aminoglycoside aptamer with a K_D of 0.5 mM. This LoD is $> 5\times$ better than those measured using standard SWV (without S/H) yet showing $\sim 23\times$ lower power consumption. Given that aptamer switches can be synthesized for a wide range of molecules, we believe our aptamer/CMOS platform could be used for many applications in healthcare. One exciting direction is the use of our S/H CA sensor for wearable or implantable systems. This will require strategies for mitigating the effect of EMI including shielding of the sensing probe, differential measurements using multiple channels to improve the common-mode rejection (especially the 50/60 Hz power-line coupling), and a more integrated approach between the electronics and the aptamer-sensor probes. These topics are potential avenues for future research.

Acknowledgment

The authors would like to thank TSMC University Shuttle Program for chip fabrication, Mentor Graphics, Dr. Peter L. Mage, Vlad Kesler, Nico Maganzini for the insightful discussions, and Ahmed Sawaby for the help in the CAD tool.

This work was supported by Stanford Precision Health and Integrated Diagnostic Center (PHIND), National Institute of Health (NIH) SPARC Program (OT2OD025342), NIH NIBIB (R01EB025867), National Science Foundation (NSF) CAREER Award (ECCS-1454107), and the Chan-Zuckerberg Biohub.

Appendix

A.: Calibration using SWV to track the drift in redox potential

As chronoamperometry (CA) lacks the capability of tracking the redox potential (due to either drifts in the redox molecules or the electrode materials), it is crucial to incorporate voltammetry to frequently calibrate and re-adjust the voltage window used in the CA measurements. To demonstrate the efficacy of such a calibration technique, we prepare an aptamer probe with two reference electrode materials (Ag/AgCl and Pt) and perform hybrid SWV/CA measurements. We first measure the potential peak from SWV, adjust the two voltage levels for CA, and then extract the kinetics information from the MB-tethered aptamers. Fig. 19 shows the seven sequential configurations employed in this experiment, SWV results from both Ag/AgCl and Pt reference electrodes, and the extracted kinetics when the probe is immersed in 0.5-mM kanamycin solution. Results show that the kinetics information can be tracked and recovered by adjusting the potential window according to the SWV measurements with a maximum error of 2.5%. On the other hand, > 20% of error is observed without proper adjusting the potential levels. We believe the residual 2.5% error is limited by the perturbation of the aptamer thermal equilibrium due to sudden changes in the potential range used in each measurement.

B.: Two- vs. three-electrode electrochemical cell

Generally, a three-electrode electrochemical cell is employed to minimize the effect of voltage drop due to the ionic resistance from the medium. Nonetheless, two-electrode cell can still be utilized if such a voltage drop is small enough due to either low current level or small ionic resistance. To justify this, we performed electrochemical impedance spectroscopy (EIS) on our implanted probe with different probe configurations in both saline buffer and human whole blood (Fig. 20). In Fig. 20(a), the open section in Au and Ag/AgCl electrodes are offset against each other to avoid electrical shorting. On the other hand, Fig. 20(b) has both the open section lie in parallel with each other with space defined by the thickness of the heat-shrink plastics. EIS measurements from 1 – 10 MHz show that a medium resistance of 550 and 320 Ω in 1 $\times$ SSC for configuration Fig. 20(a) and Fig. 20(b), respectively. The resistance measured in human whole blood is approximately 4 $\times$ higher of those measured from 1 $\times$ SSC. Such a $\sim$ 1 k Ω medium resistance will then introduce an error voltage of $\sim$ 1 mV in the fluidic potential, degrading the sensitivity. In particular, we observe undesirable sensitivity reduction in Fig. 20(a) configuration. Therefore, we have employed a fully exposed Ag/AgCl electrode in our implanted probe (Fig. 5(b)) to maximize the RE electrode surface area and to minimize the medium resistance. Fig. 20(c) compares the measured SWV waveforms (using PalmSens EmStat3) with aptamers in buffer solution between the two- and three-electrode setup. Negligible difference is observed in the measured current peak. Here SWV is employed as it offers better visualization resolution.

C.: In vitro long-term study of the aptamer sensors

The readers may also be interested in the longevity of the aptamers when challenged in whole blood. According to the recently published *in vivo* studies, these aptamer sensors have been tested for ~4 hrs in anesthetized rodents [17] or 12 hrs in awake animals (using an external wired connection between the implanted device and the instrument) [16]. In both cases, the limit of the aptamer sensors cannot be reached due to animal experimental constraints. To study aptamer longevity, we establish an *in vitro* system that mimics the human blood circulation and incubate the sensing probe with EDTA-treated (anti-coagulant) human whole blood samples (BioIVT Inc.) at room temperature (Fig. 21(a)). We prepare two blood samples, spiked with 0 and 0.5 mM kanamycin concentrations, and alternate them manually using fluidic valves to study the sensitivity degradation as a function of time. Fig. 21(b) demonstrates a representative result in which SWV has been employed. Though we discover fluidic mixing between the blood samples post-experimentally, the data is still quite informative for us to draw a few conclusions. In summary, the aptamers are stable for > 24 hours, which is decent for our intended drug monitoring applications. Second, the aptamers are sensitive up to four days at a reduced SNR; thus, daily calibration for longer-term use will be mandatory. It is worth noting that these were measured under continuous interrogation of voltammetry without any measurement pausing, which to our belief affects the aptamer integrity due to electrostatic actuation. In other words, aptamers get stripped off from the electrode surface, causing signal degradation. We believe the sensor lifetime can be further extended with smart measurement scheduling. Improvement in surface chemistry can also be pursued. For example, the aptamers can be functionalized to the gold surface with tri-thiol bonds [59] instead of the single bond and can be functionalized to different electrode materials such as graphene to promote covalent bonding [28].

In this long-term *in vitro* study, we protected our sensing probe with a poly(ether)-sulfone (PES) membrane filter (Spectrum Labs Inc.) having a pore size that can block blood cells or biomolecules exceeding 750 kDa from entering. The long settling time shown in Fig. 21(b) is thus limited by the drug diffusing across the membrane at a thickness of 100 μm but not the aptamer response time. In our recent work, we have focused on coating our sensor device with a thin layer of biocompatible hydrogel such as poly(ethylene glycol) or polyacrylamide, which offers a smaller pore size (< 3 nm in diameter) yet with potential anti-fouling capability. This small pore size will also help protect the aptamers from being degraded by the deoxyribonuclease (DNase, with a molecular weight ranging from 40 ~ 60 kDa) and can trap the aptamers within the device after detaching from the electrode surface, thus preventing any potential immunogenicity.

D.: Techniques for temporal resolution enhancement and power reduction

As shown in Fig. 4, CA generally employs a square-wave potential at 50% duty cycle. As the signal-of-interest takes ~10 msec of recording, it is possible to employ non-50% duty-cycle square-wave to further enhance the temporal resolution. To illustrate the idea, Fig. 22 demonstrates CA with ~10% duty cycle and the results at different target concentration (measured with a commercial potentiostat as our CMOS chip cannot be configured to generate such a non-50% duty cycle waveform). Binding curve analysis also shows an

identical K_D as measured from standard SWV. By matching the temporal resolution to those employed in dopamine monitoring [36], it is therefore possible to adapt the aptamer technology for *in vivo* neurotransmitter monitoring in the brain according to the recent developed dopamine and serotonin aptamers [53].

As mentioned earlier, the amplifiers $A_1 - A_3$ are designed targeting at 1nA_{rms} when loaded with 100-nF cell capacitance. With S/H technique, its power consumption can be further reduced to meet merely the settling requirement. Based on our simulation, a $\sim 2\times$ power reduction in $A_1 - A_3$ is possible with minimal impact on the sampling noise.

Biographies

Jun-Chau Chien (S'05–M'19) received the B.S. degree in Electrical Engineering from the National Taiwan University in 2004, the M.S. degree in Electronics Engineering from the National Taiwan University, in 2006, and the Ph.D. degree in Electrical Engineering from the University of California at Berkeley in 2015. He received the postdoctoral training from 2017–2018 at Stanford University and is currently a Research Engineer, also at Stanford University.

From 2008 to 2014, he was with Berkeley Wireless Research Center (BWRC). He held industrial positions at HMicro (now LifeSignals Inc.), Xilinx Inc., InvenSense (now TDK corporation), and INanoBio Inc. His research topics include integrated microsystems for *in vitro* and *in vivo* biosensing, high-speed millimeter-wave and mixed-signal circuits and systems, and electronic techniques for VNA calibration.

Dr. Chien was the recipient of the 2019 CICC Outstanding Regular Paper Award, 2014 Microwave Theory and Techniques Society (MTT-S) Graduate Fellowship for Medical Applications, the 2014 Solid-State Circuit Society (SSCS) Predoctoral Achievement Award, the 2013–2014 Outstanding Graduate Student Instructor Award of the University of California at Berkeley, the 2014 Analog Devices Outstanding Design Award, the 2008 Berkeley Wireless Research Center Fellowship, the 2007 International Solid-State Circuits Conference (ISSCC) Silk Road Award, and the 2006 Outstanding Research Award and Annual Best Thesis Award of the Graduate Institute of Electronics Engineering, National Taiwan University, Taipei, Taiwan. He was a co-recipient of the 2010 Jack Kilby Award for Outstanding Student Paper for his work on a 90 GHz pulser with 30 GHz of bandwidth for medical imaging.

Sam Baker received a B.A. in Zoology from the University of Cambridge, Cambridge, U.K., in 2008, and the VetMB in Veterinary Medicine from the University of Cambridge, Cambridge, U.K., in 2011.

In 2011, he began a residency in Laboratory Animal Medicine at Columbia University, NY, USA, becoming a Diplomate of the American College of Laboratory Animal Medicine in 2014. From 2014–2016 he worked as a Clinical Veterinarian in the Institute of Comparative Medicine at Columbia University, NY, USA. He is currently a Staff Veterinarian in the Veterinary Service Center at Stanford University, CA, USA. He specializes in the perioperative care of laboratory animals, working with researchers to develop and refine animal research models.

H. Tom Soh received the B.S. degree with a double major in Mechanical Engineering and Materials Science with Distinction from Cornell University in 1992, and the M.S. and the Ph.D. degree in Electrical Engineering from Stanford University in 1995 and 1999, respectively. Between 1999 and 2003, he served as a technical manager of MEMS device research group at Bell Laboratories and Agere Systems. Between 2003 and 2015, he was the Ruth Garland Professor at UC-Santa Barbara (UCSB) in the department of Mechanical Engineering and Materials. He is currently a Professor of Electrical Engineering and Radiology at Stanford University. His lab is interested in developing synthetic reagents that can perform useful molecular functions and integrating them into biosensor systems for the early detection and individualized treatment of diseases.

He is a recipient of numerous awards including MIT Technology Review's "TR 100" Award, ONR Young Investigator Award, Beckman Young Investigator Award, ALA Innovator Award, NIH Director's TR01 Award, NIH Edward Nagy Award, Guggenheim Fellowship, and Alexander van Humboldt Fellowship. Dr. Soh is a Chan-Zuckerberg Biohub Investigator, fellow of the American Institute for Medical and Biological Engineering (AIMBE), and member of the National Academy of Inventors (NAI).

Amin Arbabian (S'06–M'12–SM'17) received the Ph.D. degree in electrical engineering and computer science from the University of California at Berkeley, Berkeley, CA, USA, in 2011. From 2007 to 2008, he was a part of the Initial Engineering Team, Tagarray, Inc., Palo Alto, CA, USA (now acquired by Maxim Integrated Inc.). In 2010, he joined Qualcomm's Corporate Research and Development Division, San Diego, CA, USA, where he designed circuits for next-generation ultralow power wireless transceivers. In 2012, he joined Stanford University, Stanford, CA, USA, where he is now an Associate Professor of electrical engineering. His current research interests include mm-wave and high-frequency circuits and systems, imaging technologies, Internet-of-Everything devices including wireless power delivery techniques, and medical implants.

Dr. Arbabian was a recipient or co-recipient of the 2020 *IEEE* Transactions on Biomedical Circuits and Systems Best Paper Award, 2016 Stanford University Tau Beta Pi Award for Excellence in Undergraduate Teaching, the 2015 NSF CAREER Award, the 2014 DARPA Young Faculty Award including the Director's Fellowship in 2016, the 2013 Hellman Faculty Scholarship, the 2010–2011, 2014–2015, and 2016–2017 Qualcomm Innovation Fellowships, and best paper awards at the 2017 *IEEE* Biomedical Circuits and Systems Conference, the 2016 *IEEE* Conference on Biomedical Wireless Technologies, Networks, and Sensing Systems, the 2014 *IEEE* VLSI Circuits Symposium, the 2013 *IEEE* International Conference on Ultra-Wideband, the 2010 *IEEE* Jack Kilby Award for Outstanding Student Paper at the International Solid-State Circuits Conference, and two-time second place best student paper awards at 2008 and 2011 RFIC Symposiums. He currently serves on the steering committee for RFIC Symposium, the technical program committees of RFIC Symposium and VLSI Circuits Symposium, and as an Associate Editor for *IEEE* Solid-State Circuits Letters and the *IEEE* Journal of Electromagnetics, RF and Microwaves in Medicine and Biology.

REFERENCES

- [1]. Felici A, Verweij J, and Sparreboom A, "Dosing strategies for anticancer drugs: The good, the bad and body-surface area," *Eur. J. Cancer*, vol. 38, no. 13, pp. 1677–1684, 2002. [PubMed: 12175683]
- [2]. Rizk ML et al., "Considerations for dose selection and clinical pharmacokinetics/pharmacodynamics for the development of anti-bacterial agents," *Antimicrob. Agents Chemother.*, vol. 63, no. 5, pp. 1–13, 2019.
- [3]. Mould DR and Hutson PR, "Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future," *J. Clin. Pharmacol.*, vol. 57, pp. S116–S128, 2017. [PubMed: 28921645]
- [4]. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, and Rubens RD, "Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry," *Cancer Chemother. Pharmacol.*, vol. 36, no. 6, pp. 473–476, 11 1995. [PubMed: 7554038]
- [5]. Li J, Liang JY, Laken SJ, Langer R, and Traverso G, "Clinical Opportunities for Continuous Biosensing and Closed-Loop Therapies," *Trends Chem.*, vol. 2, no. 4, pp. 319–340, 4 2020.
- [6]. Tucker GT, "Personalized Drug Dosage – Closing the Loop," *Pharm. Res.*, vol. 34, no. 8, pp. 1539–1543, 1 2017. [PubMed: 27943015]
- [7]. Rawson TM et al., "Delivering precision antimicrobial therapy through closed-loop control systems," *J. Antimicrob. Chemother.*, vol. 73, no. 4, pp. 835–843, 2018. [PubMed: 29211877]

- [8]. Polasek TM, Shakib S, and Rostami-Hodjegan A, "Precision dosing in clinical medicine: present and future," *Expert Rev. Clin. Pharmacol.*, vol. 11, no. 8, pp. 743–746, 7 2018. [PubMed: 30010447]
- [9]. Undevia SD, Gomez-Abuin G, and Ratain MJ, "Pharmacokinetic variability of anticancer agents," *Nat. Rev. Cancer*, vol. 5, no. 6, pp. 447–458, 6 2005. [PubMed: 15928675]
- [10]. Ates HC, Roberts JA, Lipman J, Cass AEG, Urban GA, and Dincer C, "On-Site Therapeutic Drug Monitoring," *Trends Biotechnol.*, vol. xx, no. xx, pp. 1–16, 2020.
- [11]. Wen W, Yan X, Zhu C, Du D, and Lin Y, "Recent Advances in Electrochemical Immunosensors," *Anal. Chem.*, vol. 89, no. 1, pp. 138–156, 11 2017. [PubMed: 28105820]
- [12]. Cho IH et al., "Current technologies of electrochemical immunosensors: Perspective on signal amplification," *MDPI Sensors*, vol. 18, no. 1, pp. 1–18, 1 2018.
- [13]. van den Broek I, Niessen WMA, and van Dongen WD, "Bioanalytical LC-MS/MS of protein-based biopharmaceuticals," *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.*, vol. 929, pp. 161–179, 4 2013.
- [14]. Traylor MJ, Tchoudakova AV, Lundquist AM, Gill JE, Boldog FL, and Tangarone BS, "Comprehensive Discovery and Quantitation of Protein Heterogeneity via LC-MS/MS Peptide Mapping for Clone Selection of a Therapeutic Protein," *Anal. Chem.*, vol. 88, no. 18, pp. 9309–9317, 8 2016. [PubMed: 27569415]
- [15]. Ferguson BS et al., "Real-time, aptamer-based tracking of circulating therapeutic agents in living animals," *Sci. Transl. Med.*, vol. 5, no. 213, 11 2013.
- [16]. Arroyo-Currás N, Somerson J, Vieira PA, Ploense KL, Kippin TE, and Plaxco KW, "Real-time measurement of small molecules directly in awake, ambulatory animals," *Proc. Natl. Acad. Sci.*, vol. 114, no. 4, pp. 645–650, 1 2017. [PubMed: 28069939]
- [17]. Mage PL, Ferguson BS, Maliniak D, Ploense KL, Kippin TE, and Soh HT, "Closed-loop control of circulating drug levels in live animals," *Nat. Biomed. Eng.*, vol. 1, no. 5, pp. 1–10, 5 2017.
- [18]. Wilson BD, Hariri AA, Thompson IAP, Eisenstein M, and Soh HT, "Independent control of the thermodynamic and kinetic properties of aptamer switches," *Nat. Commun* 10, 5079, pp. 1–9, 11 2019. [PubMed: 30602773]
- [19]. Idili A et al., "Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan: In situ in the living body," *Chem. Sci.*, vol. 10, no. 35, pp. 8164–8170, 7 2019. [PubMed: 31673321]
- [20]. Dauphin-Ducharme P et al., "Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery," *ACS Sensors*, vol. 4, no. 10 pp. 2832–2837, 10 2019. [PubMed: 31556293]
- [21]. Arroyo-Currás N et al., "High-Precision Control of Plasma Drug Levels Using Feedback-Controlled Dosing," *ACS Pharmacol. Transl. Sci.*, vol. 1, no. 2, pp. 110–118, 11 2018. [PubMed: 32219207]
- [22]. Bock L, Griffin L, Latham J et al., "Selection of single-stranded DNA molecules that bind and inhibit human thrombin," *Nature* 355, pp. 564–566, 1992. [PubMed: 1741036]
- [23]. Ellington A and Szostak J, "*In vitro* selection of RNA molecules that bind specific ligands," *Nature* 346, pp. 818–822, 1990. [PubMed: 1697402]
- [24]. Tuerk C and Gold L, "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase," *Science*, vol. 249, no. 4968, pp. 505–510, 8 1990. [PubMed: 2200121]
- [25]. Chien JC, Mage PL, Soh HT, and Arbabian A, "An Aptamer-based Electrochemical-Sensing Implant for Continuous Therapeutic- Drug Monitoring in vivo," *IEEE Symp. VLSI Circuits, Dig. Tech. Pap.*, 6 2019, pp. C312–C313.
- [26]. Augustyniak M et al., "A 24×16 CMOS-based chronocoulometric DNA microarray," *IEEE Int. Solid-State Circuits Conf. (ISSCC)*, 2 2006, pp. 59–68.
- [27]. Jafari HM, Abdelhalim K, Soleymani L, Sargent EH, Kelley SO, and Genov R, "Nanostructured CMOS wireless ultra-wideband label-free PCR-free DNA analysis SoC," *IEEE J. Solid-State Circuits*, vol. 49, no. 5, pp. 1223–1241, 5 2014.
- [28]. Manickam A et al., "A CMOS Electrochemical Biochip with 32 × 32 Three-Electrode Voltammetry Pixels," *IEEE J. Solid-State Circuits*, vol. 54, no. 11, pp. 2980–2990, 11 2019.

- [29]. Levine PM, Gong P, Levicky R, and Shepard KL, "Active CMOS sensor array for electrochemical biomolecular detection," *IEEE J. Solid-State Circuits*, vol. 43, no. 8, pp. 1859–1871, 8 2008.
- [30]. Hall DA et al., "A nanogap transducer array on 32nm CMOS for electrochemical DNA sequencing," *IEEE Int. Solid-State Circuits Conf*, 2 2016, pp. 288–289.
- [31]. Sun AC, Alvarez-Fontecilla E, Venkatesh AG, Aronoff-Spencer E, and Hall DA, "High-Density Redox Amplified Coulostatic Discharge-Based Biosensor Array," *IEEE J. Solid-State Circuits*, vol. 53, no. 7, pp. 2054–2064, 7 2018. [PubMed: 30559530]
- [32]. Liao YT, Yao H, Lingley A, Parviz B, and Otis BP, "A 3- μ W CMOS glucose sensor for wireless contact-lens tear glucose monitoring," *IEEE J. Solid-State Circuits*, vol. 47, no. 1, pp. 335–344, 1 2012.
- [33]. Agarwal A et al., "A 4 μ W, ADPLL-based implantable amperometric biosensor in 65nm CMOS," *IEEE Symp. VLSI Circuits, Dig. Tech. Pap*, 6 2017, pp. C108–C109.
- [34]. Jiang H, Zhou X, Kulkarni S, Uranian M, Seenivasan R, and Hall DA, "A Sub-1 μ w multiparameter injectable BioMote for continuous alcohol monitoring," *IEEE Cust. Integr. Circuits Conf*, 4 2018, pp. 1–4.
- [35]. Detection SD, Nasri B, Wu T, Member S, Alharbi A, and Member S, "Hybrid CMOS-Graphene Sensor Array for Subsecond Dopamine Detection," *IEEE J. Solid-State Circuits* vol. 11, no. 6, pp. 1192–1203, 12 2017.
- [36]. Bozorgzadeh B, Covey DP, Howard CD, Garriss PA, and Mohseni P, "A neurochemical pattern generator SoC with switched-electrode management for single-chip electrical stimulation and 9.3 μ w, 78 pArms, 400 V/s FSCV sensing," *IEEE J. Solid-State Circuits*, vol. 49, no. 4, pp. 881–895, 4 2014.
- [37]. Guo J, Ng W, Yuan J, Li S, and Chan M, "A 200-Channel Area-Power-Efficient Chemical and Electrical Dual-Mode Acquisition IC for the Study of Neurodegenerative Diseases," *IEEE Trans. Biomed. Circuits Syst*, vol. 10, no. 3, pp. 567–578, 3 2016. [PubMed: 26529782]
- [38]. Dorta-Quinones CI, Wang XY, Dokania RK, Gailey A, Lindau M, and Apsel AB, "A Wireless FSCV Monitoring IC with Analog Background Subtraction and UWB Telemetry," *IEEE Trans. Biomed. Circuits Syst*, vol. 10, no. 2, pp. 289–299, 4 2016. [PubMed: 26057983]
- [39]. Chien J, Soh HT, and Arbabian A, "26.4 A Cell-Capacitance-Insensitive CMOS Sample-and-Hold Chronoamperometric Sensor for Real-Time Measurement of Small Molecule Drugs in Whole Blood," *IEEE Int. Solid-State Circuits Conf. (ISSCC)*, 2 2020, pp. 406–407.
- [40]. Dauphin-Ducharme P and Plaxco KW, "Maximizing the signal gain of electrochemical-DNA sensors," *Anal. Chem*, vol. 88, no. 23, pp. 11654–11662, 12 2016. [PubMed: 27805364]
- [41]. Dauphin-Ducharme P, Arroyo-Currás N, Kurnik M, Ortega G, Li H, and Plaxco KW, "Simulation-based approach to determining electron transfer rates using square-wave voltammetry," *Langmuir*, vol. 33, no. 18, pp. 4407–4413, 5 2017. [PubMed: 28391695]
- [42]. Arroyo-Currás N, Dauphin-Ducharme P, Ortega G, Ploense KL, Kippin TE, and Plaxco KW, "Subsecond-resolved molecular measurements in the living body using chronoamperometrically interrogated aptamer-based sensors," *ACS Sensors*, vol. 3, no. 2, pp. 360–366, 2 2018. [PubMed: 29124939]
- [43]. Dauphin-Ducharme P et al., "Chain dynamics limit electron transfer from electrode-bound, single-stranded oligonucleotides," *J. Phys. Chem. C*, vol. 122, no. 37, pp. 21441–21448, 9 2018.
- [44]. Woolley CF, Hayes MA, Mahanti P, Douglass Gilman S, and Taylor T, "Theoretical limitations of quantification for noncompetitive sandwich immunoassays," *Anal. Bioanal. Chem*, vol. 407, no. 28, pp. 8605–8615, 9 2015. [PubMed: 26342315]
- [45]. Acciaroli G, Vettoretti M, Facchinetti A, and Sparacino G, "Calibration of minimally invasive continuous glucose monitoring sensors: State-of-the-art and current perspectives," *MDPI Biosensors*, vol. 8, no. 24, pp. 1–17, 3 2018.
- [46]. gang Yu Z and Lai RY, "A reagentless and reusable electrochemical aptamer-based sensor for rapid detection of ampicillin in complex samples," *Talanta*, vol. 176, no. August 2017, pp. 619–624, 8 2018. [PubMed: 28917799]

- [47]. Schoukroun-Barnes LR, Macazo FC, Gutierrez B, Lottermoser J, Liu J, and White RJ, "Reagentless, Structure-Switching, Electrochemical Aptamer-Based Sensors," *Annu. Rev. Anal. Chem.*, vol. 9, pp. 163–181, 6 2016.
- [48]. Arroyo-Currás N, Scida K, Ploense KL, Kippin TE, and Plaxco KW, "High surface area electrodes generated via electrochemical roughening improve the signaling of electrochemical aptamer-based biosensors," *Analytical Chemistry*, vol. 89, no. 22 pp. 12185–12191, 11 2017. [PubMed: 29076341]
- [49]. Liu J, Wagan S, Dávila Morris M, Taylor J, and White RJ, "Achieving reproducible performance of electrochemical, folding aptamer-based sensors on microelectrodes: Challenges and prospects," *Anal. Chem.*, vol. 86, no. 22, pp. 11417–11424, 11 2014. [PubMed: 25337781]
- [50]. Bard Allen J and Faulkner Larry R, *Electrochemical Methods: Fundamentals and Applications* John Wiley & Sons Inc., 2001.
- [51]. Bell CG, "The long-time chronoamperometric current at an inlaid microband (or Laminar) electrode," *Sensors*, vol. 13, no. 1, pp. 626–647, 1 2013. [PubMed: 23291578]
- [52]. Ricci F et al., "Surface chemistry effects on the performance of an electrochemical DNA sensor," *Bioelectrochemistry*, vol. 76, no. 1–2, pp. 208–213, 3 2009. [PubMed: 19362061]
- [53]. Nakatsuka N et al., "Aptamer-field-effect transistors overcome Debye length limitations for small-molecule sensing," *Science* (80), vol. 362, no. 6412, pp. 319–324, 2018.
- [54]. Kalra, Dhiman A, Cho WC, Bruno JG, and Sharma TK, "Simple methods and rational design for enhancing aptamer sensitivity and specificity," *Front. Mol. Biosci.*, vol. 5, pp. 1–16, 5 2018. [PubMed: 29417049]
- [55]. Hines EL, Llobet E, and Gardner JWJW, "Electronic noses: a review of signal processing techniques," *IEE Proceeding online*, vol. 146, no. 6, pp. 297–310, 12 1999.
- [56]. Chiu SW et al., "A fully integrated nose-on-a-chip for rapid diagnosis of ventilator-associated pneumonia," *IEEE Trans. Biomed. Circuits Syst.*, vol. 8, no. 6, pp. 765–778, 12 2014. [PubMed: 25576573]
- [57]. Moon HG et al., "Chemiresistive Electronic Nose toward Detection of Biomarkers in Exhaled Breath," *ACS Appl. Mater. Interfaces*, vol. 8, no. 32, pp. 20969–20976, 7 2016. [PubMed: 27456161]
- [58]. Armbruster DA and Pry T, "Limit of blank, limit of detection and limit of quantitation.,", *Clin. Biochem. Rev.*, vol. 29 Suppl(i), pp. S49–52, 8 2008. [PubMed: 18852857]
- [59]. Phares N, White RJ, and Plaxco KW, "Improving the stability and sensing of electrochemical biosensors by employing trithiol-anchoring groups in a six-carbon self-assembled monolayer," *Analytical Chemistry*, vol. 81, no. 3 pp. 1095–1100, 2 2009. [PubMed: 19133790]

Fig. 1.

(a) Real-time therapeutic drug monitoring enables precision drug dosing for optimal treatment outcome. We envision using a real-time biosensor in the clinical setting during the course of drug administration. The interfacing electronics can be mounted on the patient's skin with wireless data telemetry. (b) An illustration of drug concentration in blood plasma with and without closed-loop control and a generic closed-loop drug control system.

Fig. 2.

The operation of structure-switching aptamer with and without the presence of the drug and its use in in vivo monitoring.

Fig. 3.

(a) SWV operation. (b) SWV voltammograms at 400 Hz at different kanamycin concentrations. (c) Measured time-series at 400 and 60 Hz SWV frequencies. (d) Fitting of the binding curve with Langmuir isotherm model.

Fig. 4.

(a) A cyclic voltammogram of methylene blue (MB) and the selection of voltages in chronoamperometry. The electron transfer kinetics can be measured from MB through (b) the reduction and (c) the oxidation processes.

Fig. 5.

(a) in vivo demonstration with a rodent model. (b) The photo of the implanted probe. (c) Measured responses of two aptamers.

Fig. 6.
Monte Carlo simulation for studying impact of electronics noise.

Fig. 7.

(a) The system block diagram of a conventional electrochemical-sensing circuit. (b) PSD illustration of noise peaking.

Fig. 8.

(a) Proposed CA with sample-and-hold operation. (b) Simplified circuit schematics in the potential-tracking phase. (c) Simplified circuit schematics during the hold phase.

Fig. 9.

(a) Complete circuit schematics. (b) Operational timing diagram.

Fig. 10.

Circuit schematics: (a) OTAs. (b) RGC. (c) Dual-slope ADC. (d) Tri-switch. (e) R-2R DAC.

Fig. 11.

Die micrograph. The active circuits are highlighted and occupy an area of $700\ \mu\text{m} \times 550\ \mu\text{m}$, mainly dominated by the amplifiers $A_1 - A_3$.

Fig. 12.

(a) A schematic illustration of the experimental setup. (b) A photo of our measurement setup with Faraday cage. (c) A photo of the system inside the Faraday cage. The aptamer-functionalized probe is immersed into blood samples at different kanamycin concentrations. The sensing electrodes (RE and WE) are connected to the chip PCB using two electrical wires.

Fig. 13.

Measured $V_{WE} - V_{RE}$ settling behaviors. (a) A proper settling with potential difference of 425 mV is achieved within the designated time. (b) An example of improper settling when the potential difference is > 450 mV.

Fig. 14.

Measured time-domain waveforms and PSDs with S/H: (a) disabled and (b) enabled. In both cases, a 55-Hz sinusoidal current at different amplitude is injected into the current conveyor. The circuit is loaded with an equivalent circuit model during the measurements. In (a), the measurement is conducted at a mirror gain of 1, an ADC I_{ref} of 2 μ A, and an ADC integrator capacitor of 1 pF. In (b), the measurement is conducted at a mirror gain of 8, an ADC I_{ref} of 0.5 μ A, and an ADC integrator capacitor of 0.5 pF. The 2nd-order nonlinearity is primarily due to its single-ended nature when measured at low-bias current.

Fig. 15.

- (a) Measured electrode waveforms ($V_{WE} - V_{RE}$) when interfacing with an aptamer device.
 (b) A zoom-in of the first pulse. (c) Waveforms during the hold phases. The voltage drooping within the region-of-interest (ROI) is limited to $< 5\text{mV}$.

Fig. 16.

Measured current responses. At each concentration, an overlap of 100 measured transient waveforms is provided to demonstrate the repeatability. Each transient waveform is normalized to its first sample in order to provide better visual observation of the kinetics difference. At each concentration, an average curve from all the measurements is provided. The measurement is conducted at a mirror gain of 1, an ADC I_{ref} of 2 μA , and an ADC integrator capacitor of 1 pF.

Fig. 17.

(a) Plotting of the extracted τ_1 and I_1 from the un-normalized current transients at three different kanamycin concentration. (b) The cause of the distribution in τ_1 and I_1 . A linear correlation between τ_1 and I_1 is observed, which motivates the use of principal component analysis (PCA) to compensate for such an error and to improve the limit-of-detection (LoD).

Fig. 18.

Extracted principal component (a) vs. time and (b) vs. concentration. Error bar stands for one standard deviation ($n = 100$ for each concentration).

Fig. 19.

The study of using SWV as calibration to track the drift in the redox potential. (a) Seven different measurement settings with two different RE materials (Ag/AgCl and Pt) and two distinct potential windows are mixed and matched to study the effectiveness of the calibration. (b) The extracted kinetics information from the seven sequential measurements and the associated error relative to the first one.

Fig. 20.

The study of employing two electrodes (WE and RE) for electrochemical detection. The opening of the two electrodes are configured (a) to offset from each other to avoid shorting and (b) in parallel to minimize the ionic resistance. (c) A comparison of SWV voltammograms.

Fig. 21.

(a) An *in vitro* blood circulation setup to study the aptamer lifetime. (b) Measured aptamer responses at different days when alternating between two samples at 0 and 0.5 mM kanamycin concentrations.

Fig. 22.

The electron-transfer kinetics can be extracted successfully with non-50% duty-cycled CA potentials. (a) Stepping between -0.5V to -0.3V and (b) -0.2V to -0.4V .

Table I.

A comparison between SWV and CA.

	Square-wave Voltammetry (SWV)	Chronoamperometry (CA)
Kinetic measurements	Indirect	Direct
Temporal resolution	2 sec per scan (< 0.5 Hz)	< 0.2 sec (> 5 Hz)
Current drift compensation	Requires 2 scans at different SWV frequency	Direct time-constant extraction
Curve-fitting error	Sensitive to background level	Less sensitive
V_{peak} tracking	Yes	No

Table II.**Design Specification**

Biosensor	
Electrode area	0.25 mm ² (Au)
Probe density	~1% (10 ¹² /cm ²)
Self-assembly monolayer	6-mercapto-1-hexanol HS(CH ₂) ₆ OH
Electrode capacitance C _{DL}	w/o passivation: ~60 nF (1× SSC) ~36 nF (whole blood) w/ passivation: ~10 nF (1× SSC) ~9 nF (whole blood)
Drug Target	Kanamycin monosulfate C ₁₈ H ₃₆ N ₄ O ₁₁ · H ₂ SO ₄ (Aminoglycoside)
Aptamer sequence	5'-GGGACTTGTTTAGGTAATGAGTCCC-3'
Redox label	Methylene blue
Redox kinetics (τ ₀)	1.2 ~ 3 msec (1:2.5)
Molecular resolution	< 10 μM (K _D = 0.5 mM)
Chronoamperometric Sensor	
Dynamic range	60 dB
Bandwidth	2.5 kHz
Electronics noise	< 250 pA _{rms}
Potential ranges	-0.4 ~ -0.2V (adjustable)
Acquisition rate	5 ~ 10 Hz

Table III.

Performance Comparison

Electronics	Voltammetry Mode	Acquisition Time (per Sample)	Energy Consumption (per Sample)	Molecular Noise Floor (SNR = 1)	Limit of Detection (SNR = 3.3)
Palmsens EmStat3	SWV with KDM	8 sec (2 SWV scans)	n.a.	1.5 μM	5 μM
CMOS [25]	SWV with KDM	8 sec (2 SWV scans)	50 mJ	18 μM	59.4 μM
CMOS [This work]	CA + S/H	0.1 sec	22 μJ	12.3 μM	40.6 μM
CMOS [This work]	CA + S/H with average (N= 10)	1 sec	0.22 mJ	3.1 μM	10. 3 μM

Comparison Table

Table IV.

	This work		[25]	[28]	[27]	[35]	[37]	[38]	[33]	[34]
Applications	Personalized Pharmacokinetics			In vitro Diagnostics		Neuroscience			In vivo Monitoring	
Targets	Small-molecule drugs			DNA		Dopamine			Glucose/Ethanol/H ₂ O ₂	
Recognition element	Structure-switching aptamers			DNA		None (limited to electroactive molecules)			Enzyme (GOx/AOx)	
Tech.	65 nm		65 nm	250 nm	130 nm	65 nm	250 nm	65 nm	65 nm	65 nm
Voltammetry	SWV	Proposed [*] S/H-CA	swv	CV	CV	FSCV	FSCV/CV/CA	FSCV	Amp.	CA
Electrode, Area	Au, 0.25 mm ²		Au, 0.25 mm ²	a-C, 1381 μm^2	Au, 3025 μm^2	Graphene, 1000 μm^2	CFE/CNT-Au, 100 μm^2	CFM, 2400 μm^2	Pt, 0.0144mm ²	Au, 0.025mm ²
C _{DL} **	100 nF		100 nF	167 pF	800 pF	1.1 nF	1 nF	1.5 nF	n.a.	n.a.
Potentiostat ***	On-chip		On-chip	Off-chip	On-Chip	On-chip	n.a.	n.a.	On-chip	On-chip
Waveform Generator ****	On-chip		On-chip	Off-chip	On-Chip	Off-chip	Off-chip	Off-chip	On-chip	On-chip
Sensor IRN (SNR = I)	4.36 nA _{rms}	15.2 pA _{rms}	1.6 nA _{rms}	0.28 pA _{rms}	8.6 pA ^{†††}	20 pA _{rms}	93; 21.6; 0.48 pA _{rms}	92 pA _{rms}	100 pA _{rms}	1.24 nA _{rms}
Bandwidth	2.5 kHz	2.5 kHz	2 kHz	20 Hz	1 kHz	1 kHz	10; 0.25; 0.11 kHz	2 kHz	n.a.	n.a.
I _{max}	±800 nA	±2.5 nA	±800 nA	12.5 nA	350 nA	±2.56 μA	±50; ±50; ±0.2 nA	±430 nA	350 nA	80 nA
Total DR (I _{max} /I _{noise,rms})	100 dB		60 dB ^{†††}	93 dB ^{†††}	93 dB	108 dB	104 dB	79.4 dB	70.9 dB	36.1 dB
Electrochemical Data Acquisition Rate *****	0.5 Hz ^I	5 Hz ²	0.5 Hz ^I	0.167 Hz ³	0.36 Hz ⁴	100 Hz ⁵	100 Hz ⁵	100 Hz ⁵	n.a.	0.33 Hz ⁷
Power	5.25 mW	0.22 mW	6.64 mW	0.25 mW ⁵	1.142 mW	36 μW ⁵	12.1 μW ⁵	14.4 μW ⁵	4 μW ⁵⁵⁵⁵	0.97 μW ⁵⁵⁵⁵

* An off-chip 1- μF capacitor is required on the RE.

** The noise performance is dependent on the electrical double layer capacitance in the electrochemical cell.

*** Potentiostat is also termed “control amplifier” or “counter amplifier”. Both the potentiostat and waveform generator (voltage DAC) inject extra noise and consume additional power and should be highlighted when comparing performance.

**** This is referred to the time needed to acquire one electrochemical signal and is dependent on the voltammetry parameters.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

⁷ Measured lowest possible IRN.⁷⁷ Instantaneous dynamic range.⁷⁷⁷ ADC resolution limited.⁵ Current readout circuit only (per channel).⁵⁵ Two-electrode measurements with reference electrode connected to ground.⁵⁵⁵ Power of the entire implantable system.¹ SWV: $-0.5\text{ V} \sim -0.1\text{ V}$, 1 mV per step, $60/400\text{ Hz}$, with kinetics differential measurements.² CA: $-0.4 \sim -0.2\text{ V}$, 0.2 V per step.³ CV: $\pm 0.75\text{ V}$, 0.5 V/sec .⁴ CV: $-0.7 \sim 0\text{ V}$, 0.5 V/sec .⁵ FSCV, $-0.4 \sim 1.3\text{ V}$, 400 V/sec .⁶ Generally the bandwidth is below few tens of Hz.⁷ Estimated from the paper.